Posted by Michael Wonder on 06 Jul 2023
MHRA grants marketing authorisation for Opzelura (ruxolitinib) cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents
5 July 2023 - Phase 3 data supporting the approval show treatment with ruxolitinib cream resulted in improved facial and total body repigmentation, sustained and continued improvements with longer duration of treatment
Incyte Biosciences UK today announced that the MHRA has granted marketing authorisation for Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
